INSM – Insmed Incorporated
INSM — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
5.41
Margin Of Safety %
Put/Call OI Ratio
0.7
EPS Next Q Diff
-0.73
EPS Last/This Y
3.79
EPS This/Next Y
2.76
Price
131.09
Target Price
199.82
Analyst Recom
1.12
Performance Q
Upside
-209.7%
Beta
0.84
Ticker: INSM
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-07-13 | INSM | 109.11 | 0.63 | 0.94 | 108720 |
| 2026-07-14 | INSM | 110.11 | 0.63 | 4.45 | 109826 |
| 2026-07-15 | INSM | 109.76 | 0.64 | 2.45 | 110249 |
| 2026-07-16 | INSM | 107.49 | 0.65 | 0.23 | 110956 |
| 2026-07-17 | INSM | 108.32 | 0.64 | 1.26 | 112647 |
| 2026-07-20 | INSM | 107.01 | 0.67 | 0.03 | 102148 |
| 2026-07-21 | INSM | 108.62 | 0.66 | 0.04 | 102610 |
| 2026-07-22 | INSM | 106.6 | 0.63 | 0.31 | 105396 |
| 2026-07-23 | INSM | 107.49 | 0.62 | 0.00 | 109213 |
| 2026-07-24 | INSM | 106.9 | 0.61 | 1.53 | 110311 |
| 2026-07-27 | INSM | 104.7 | 0.61 | 0.03 | 110397 |
| 2026-07-28 | INSM | 104.49 | 0.61 | 0.15 | 110738 |
| 2026-07-29 | INSM | 103.17 | 0.61 | 0.05 | 110950 |
| 2026-07-30 | INSM | 101.42 | 0.61 | 1.23 | 111134 |
| 2026-07-31 | INSM | 99 | 0.60 | 0.50 | 111506 |
| 2026-08-03 | INSM | 98.85 | 0.60 | 0.11 | 112394 |
| 2026-08-04 | INSM | 99.11 | 0.59 | 1.20 | 113925 |
| 2026-08-05 | INSM | 98.95 | 0.62 | 2.16 | 118383 |
| 2026-08-06 | INSM | 132.46 | 0.66 | 0.37 | 121361 |
| 2026-08-07 | INSM | 131.19 | 0.70 | 0.26 | 129148 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-07-13 | INSM | 109.10 | 56.8 | 479.5 | -2.69 |
| 2026-07-14 | INSM | 110.11 | 59.5 | 435.3 | -2.64 |
| 2026-07-15 | INSM | 109.74 | 59.4 | 443.6 | -2.64 |
| 2026-07-16 | INSM | 107.44 | 59.4 | 456.0 | -2.64 |
| 2026-07-17 | INSM | 108.29 | 60.7 | 436.1 | -2.57 |
| 2026-07-20 | INSM | 107.05 | 60.7 | 449.3 | -2.57 |
| 2026-07-21 | INSM | 108.61 | 59.6 | 431.3 | -2.59 |
| 2026-07-22 | INSM | 106.60 | 59.6 | 454.0 | -2.59 |
| 2026-07-23 | INSM | 107.42 | 59.6 | 436.4 | -2.59 |
| 2026-07-24 | INSM | 106.95 | 59.6 | 444.2 | -2.59 |
| 2026-07-27 | INSM | 104.73 | 59.6 | 455.2 | -2.59 |
| 2026-07-28 | INSM | 104.13 | 59.8 | 445.2 | -2.59 |
| 2026-07-29 | INSM | 103.15 | 59.8 | 447.7 | -2.59 |
| 2026-07-30 | INSM | 101.43 | 59.8 | 452.5 | -2.59 |
| 2026-07-31 | INSM | 98.60 | 59.8 | 460.7 | -2.59 |
| 2026-08-03 | INSM | 98.43 | 59.8 | 442.5 | -2.59 |
| 2026-08-04 | INSM | 98.43 | 59.8 | 442.5 | -2.59 |
| 2026-08-05 | INSM | 98.89 | 58.3 | 440.4 | -2.63 |
| 2026-08-06 | INSM | 132.62 | 58.3 | 209.1 | -2.63 |
| 2026-08-07 | INSM | 131.09 | 59.9 | 448.8 | -2.63 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-07-13 | INSM | -17.04 | 3.99 | 7.47 |
| 2026-07-14 | INSM | -16.04 | 3.99 | 7.47 |
| 2026-07-15 | INSM | -16.33 | 3.99 | 7.47 |
| 2026-07-16 | INSM | -16.33 | 3.99 | 7.47 |
| 2026-07-17 | INSM | -16.33 | 3.99 | 7.47 |
| 2026-07-20 | INSM | -16.33 | 5.70 | 7.47 |
| 2026-07-21 | INSM | -16.33 | 5.70 | 7.47 |
| 2026-07-22 | INSM | -16.33 | 5.70 | 7.47 |
| 2026-07-23 | INSM | -15.96 | 5.70 | 7.47 |
| 2026-07-24 | INSM | -15.96 | 5.70 | 7.47 |
| 2026-07-27 | INSM | -16.33 | 3.86 | 5.41 |
| 2026-07-28 | INSM | -16.33 | 3.86 | 5.41 |
| 2026-07-29 | INSM | -16.33 | 3.86 | 5.41 |
| 2026-07-30 | INSM | -16.33 | 3.86 | 5.41 |
| 2026-07-31 | INSM | -16.33 | 3.86 | 5.41 |
| 2026-08-03 | INSM | -16.33 | 3.80 | 5.41 |
| 2026-08-04 | INSM | -16.33 | 3.80 | 5.41 |
| 2026-08-06 | INSM | -15.85 | 3.80 | 5.41 |
| 2026-08-07 | INSM | -15.82 | 3.80 | 5.41 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.13
Avg. EPS Est. Current Quarter
-0.68
Avg. EPS Est. Next Quarter
-0.6
Insider Transactions
-15.82
Institutional Transactions
3.8
Beta
0.84
Average Sales Estimate Current Quarter
390
Average Sales Estimate Next Quarter
467
Fair Value
Quality Score
35
Growth Score
53
Sentiment Score
95
Actual DrawDown %
38.4
Max Drawdown 5-Year %
-56.5
Target Price
199.82
P/E
Forward P/E
128.58
PEG
P/S
24.98
P/B
37.78
P/Free Cash Flow
EPS
-4.11
Average EPS Est. Cur. Y
-2.63
EPS Next Y. (Est.)
0.12
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-76.94
Relative Volume
1.18
Return on Equity vs Sector %
-100
Return on Equity vs Industry %
-100
EPS 1 7Days Diff
EPS 1 30Days Diff
0.05
EBIT Estimation
448.8
◆
INSM
Healthcare
$131.10
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
73.7
Range 1M
84.9%
Sup Dist
3.5%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
73.5%
52W%
33.6%
Long-Term Value
Quality companies, undervalued
WEAK
🔴 SELL
-54.2% upside
Upside
-54.2%
Quality
35
INSM — P/E HistoricalBiotechnology
Insmed IncorporatedSector: Healthcare
Industry: Biotechnology
Employees: 1664
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
INSM
Latest News
—
Caricamento notizie per INSM…
stock quote shares INSM – Insmed Incorporated Stock Price stock today
news today INSM – Insmed Incorporated stock forecast ,stock prediction 2023 2024 2025
marketwatch INSM – Insmed Incorporated yahoo finance google finance
stock history INSM – Insmed Incorporated invest stock market
stock prices INSM premarket after hours
ticker INSM fair value insiders trading